Neurodegenerative disease and iron storage in the brain

Current Opinion in Neurology

Volumn 17, Issue 4, 2004, Pages 437-442

  Thomas, Madhavi ^a   Jankovic, Joseph ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Hallervorden spatz; Iron in the brain; Neurodegeneration; Neuroferritinopathy; Parkinsonism

Indexed keywords

CERULOPLASMIN; CHELATING AGENT; CLOQUINOL; DEFEROXAMINE; FERRITIN; FERROUS ION; IRON; NEUROMELANIN; PANTOTHENATE KINASE; PROTEIN SUBUNIT; PYRIDOXINE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VK 28;

ACERULOPLASMINEMIA; ANEMIA; ANIMAL MODEL; BIOACCUMULATION; BRAIN METABOLISM; CHELATION THERAPY; DEGENERATIVE DISEASE; ENZYME DEFICIENCY; FRIEDREICH ATAXIA; GENE MUTATION; HEMOCHROMATOSIS; HUMAN; HUNTINGTON CHOREA; INBORN ERROR OF METABOLISM; IRON KINETICS; IRON STORAGE; IRON TRANSPORT; MOTOR DYSFUNCTION; NERVE FIBER TRANSPORT; NEUROFERRITINOPATHY; NONHUMAN; PANTOTHENATE KINASE DEFICIENCY; PARKINSON DISEASE; PROTEIN PROCESSING; REGULATOR GENE; RESTLESS LEGS SYNDROME; REVIEW;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FERRITINS; HUMANS; IRON; IRON METABOLISM DISORDERS; NEURODEGENERATIVE DISEASES; NEURONS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 4043144143     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000137534.61244.d1     Document Type: Review

References (49)

1. Hallervorden J, Spatz H, Strange illness in the extrapyramidal system with special participation of the globus pallidus and the Substantia nigra: A contribution to the relations between these two centers. Z Ges Neurol Psychiat 1922; 79:254-302.
2. Shevell M. Racial hygeine, active euthanasia, and Julius Hallervorden. Neurology 1992; 12:2214-2219.
3. Shevell M. Hallervorden and history. N Engl J Med 2003; 348:3-4. This short article draws attention to Hallervorden's involvement in wartime activities, especially the T4 euthanasia program.
4. Zhou B, Westaway SK, Levinson B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001; 28:345-349.
5. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001; 28:350-354.
6. Roualt TA. Systemic iron metabolism: A review and implications for brain iron metabolism. Pediatr Neurol 2001; 25:130-137.
7. Connor JR, Menzies S, Burdo JR, Boyer PJ. Iron and iron management proteins in neurobiology. Pediatr Neurol 2001; 25:118-129.
8. Cairo G, Pietrangelo A. Iron regulatory proteins in pathobiology. Biochem J 2000; 352:241-250.
9. Ke Y, Ming Qian Z. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2003; 2:246-253. Review article on iron regulation in the brain in neurodegenerative disorders with specific attention to pantothenate kinase-associated neurodegeneration and neuroferritinopathy.
10. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical and radiographic delineation of Hallervorden-Spatz Syndrome. N Engl J Med 2003; 348:33-40. This paper comprehensively reviews the clinical presentation as well as various mutations in patients with pantothenate kinase-associated neurodegeneration.
11. Dooling EC, Schoene WC, Richardson EP Jr. Hallervorden Spatz Syndrome. Arch Neurol 1974; 30:70-83.
12. Swaiman KF. Hallervorden-Spatz Syndrome and brain iron metabolism. Arch Neurol 1991; 48:1285-1293.
13. Taylor TD, Litt M, Kramer P, et al. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Nat Genet 1996; 14:479-481.
14. Sethi KD, Adams RJ, Loring DW, el Gammal T. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol 1988; 24 (5):692-694.
15. Mollinuevo JL, Munoz E, Valldeoriola F, Tolosa E. The eye of the tiger sign in cortico-basal ganglionic degeneration. Mov Disord 1999; 14:169-171.
16. Davie CA, Barker GJ, Machado C, et al. Proton magnetic spectroscopy in Steele-Richardson-Olszewski Syndrome. Mov Disord 1997; 12:767-771.
17. Perry TL, Norman MG, Yong VW, et al. Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann Neurol 1985; 18:482-489.
18. Thomas M, Hayflick SJ, Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden Spatz Syndrome) and Pantothenate Kinase Associated Neurodegeneration. Mov Disord 2004; 8:36-42. This paper, accompanied by videos, highlights the clinical features and associated mutations in patients with PKAN with emphasis on the clinical heterogeneity of NBIA.
19. Ching KH, Westaway SK, Gitschier J, et al. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology 2002; 58:1673-1674.
20. Houlden H, Lincoln S, Farrer M, et al. Compound heterozygous PANK2 mutations confirm HARP and Hallervorden-Spatz syndromes are allelic. Neurology 2003; 61:1423-1426. This article provides insight into the relationship between PKAN and the HARP syndrome.
21. Wills AJ, Sawle GV, Guilbert PR, Curtis AR. Palatal tremor and cognitive decline in neuroferritinopathy. J Neurol Neurosurg Psychiatry 2002; 73:91-92.
22. Chinnery PF, Curtis AR, Fey C, et al. Neuroferritinopathy in a French family with late onset dominant dystonia. J Med Genet 2003; 40(5):e69.
23. Miyajima H, Nishimura Y, Mizoguchi K, et al. Familial aceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987; 37:761-767.
24. Miyajima H, Kono S, Takahashi Y, Sugimoto M. Increased lipid peroxidation and mitochondrial dysfunction in aceruloplasminemia brains. Blood Cells Mol Dis 2002; 29:433-438.
25. Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology 2003; 23:345-350. This article, written by a leading scientist in this field, reviews the clinical and pathological features of aceruloplasminemia.
26. Nielsen JE, Jensen LN, Krabbe K. Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J Neurol Neurosurg Psychiatry 1995; 59:318-321.
27. Costello DJ, Walsh SL, Harrington HJ, Walsh CH. Concurrent hereditary haemochromatosis and idiopathic Parkinson's disease: a case report series. J Neurol Neurosurg Psychiatry 2004; 75:631-633.
28. Dekker MC, Giesbergen PC, Njajou OT, et al. Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci Lett 2003; 348:117-119.
29. Leussink VI, Flachenecker P, Brechtelsbauer D, et al. Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurol Scand 2003; 107:54-61.
30. Felletschin B, Bauer P, Walter U, et al. Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci Lett 2003; 352:53-56.
31. He Y, Thong PS, Lee T, et al. Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic Biol Med 2003; 35:540-547.
32. Faucheux BA, Martin ME, Beaumont C, et al. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 2003; 86:1142-1148.
33. Double KL, Gerlach M, Schunemann V, et al. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 2003; 66:489-494.
34. Faucheux BA, Nillesse N, Damier P, et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci USA 1995; 92:9603-9607.
35. Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 2002; 59:421-424.
36. Krishnan PR, Bhatia M, Behari M. Restless legs syndrome in Parkinson's disease: a case-controlled study. Mov Disord 2003; 18:181-185.
37. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003; 61:304-309. Important and original contribution to neuropathology of restless legs syndrome and mechanisms of mishandling of iron.
38. Cosee M, Durr A, Schmitt M, et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999; 45:673-675.
39. Hou JG, Jankovic J. Movement disorders in Friedereich's ataxia. J Neurol Sci 2003; 206:59-64. Report of movement disorders other than ataxia in patients with Friedrich's ataxia.
40. Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Freidreich ataxia patients, and is associated with mitochondrial membranes. Hum Mol Genet 1997; 6:1771-1780.
41. Becker E, Richardson DR. Frataxin: its role in iron and the pathogenesis of Freidreich's ataxia. Int J Biol Chem Cell Biol 2001; 33:1-10.
42. Artuch R, Aracil A, Mas A, et al. Friedreich's ataxia: Idebenone treatment in early stage patients. Neuropediatrics 2002; 33:190-193.
43. Grabill C, Silva AC, Smith SS, et al. MRI detection of ferritin iron overload and associated neuronal pathology in iron regulatory protein-2 knockout mice. Brain Res 2003; 971:95-106. This paper helps us understand the pathophysiologic mechanisms in the IRP-2-knockout mice.
44. Thompson K, Menzies S, Muckenthaler M, et al. Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res 2003; 71:46-63.
45. Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA 1999; 96:10812-10817.
46. Loreal O, Turlin B, Pigeon C, et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 2002; 36:851-856.
47. Richardson DR. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy. Expert Opin Inv Drugs 2003; 12:235-245.
48. Shachar DB, Kahana N, Kampel V, et al. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 2004; 46:254-263.
49. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003; 37:899-909.